SecBot SecBot
COURT-RULING ·Filed Aug 11, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
BULLISH
Impact 5/10
Horizonmonths Processed3mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight ▲ Bullish

This procedural win removes a near-term distraction for Regeneron, keeping the patent case on its current track. Traders should watch for upcoming summary judgment or claim construction rulings, which could materially shift the risk profile for Eylea biosimilar competition from Amgen's Pavblu.

DirectionBullish
Confidencehigh
Horizonmonths

EYLEA HD

● Neutral Named in this court ruling
Impact
Phase
Approved
Time to market
Already approved and on the market (since August 2023)
Next catalyst
None dated

What to watchEYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$797.99
T+0 close · Aug 12, 2026 · via day close
Latest settled
+13.15%
T+60 · $902.90
Vs SPY
+18.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $797.99entry
  2. T+1 · 3mo ago +1.00%α +0.30% · $805.97
  3. T+5 · 3mo ago +5.37%α +5.81% · $840.84
  4. T+20 · 2mo ago −0.59%α +1.30% · $793.26
  5. T+60 · 12d ago +13.15%α +18.26% · $902.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The court denied Amgen's motion to remand the aflibercept (Eylea) patent litigation back to the Central District of California, keeping the MDL in the Northern District of West Virginia. This is a procedural win for Regeneron, preserving the court's familiarity with the patents and avoiding a restart in a new forum. The ruling maintains the current litigation trajectory, which has already seen all other defendants settle, leaving Amgen as the sole remaining defendant in the MDL.

Court Ruling Details

Ruling Date
Aug 11, 2026
Court
United States District Court for the Northern District of West Virginia
Court Level
District
Judge
Thomas S. Kleeh
Case Type
patent
Ruling Type
procedural
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Amgen's motion for suggestion of remand was DENIED.
  • The MDL (1:24-MD-3103) concerns Regeneron's biologic Eylea (aflibercept) patents.
  • All other defendants in the MDL have settled, leaving only Amgen.
  • The court cited its familiarity with the case and the inefficiency of remand as reasons for denial.
  • The ruling was issued by Chief Judge Thomas S. Kleeh on August 11, 2026.

Financial Impact

No monetary damages awarded or quantified in this procedural ruling. The ruling preserves the current litigation forum, avoiding potential delays and costs of a transfer.

legal costslitigation timeline

Risk Factors

  • The underlying patent infringement case against Amgen remains unresolved and could result in adverse findings.
  • Amgen may appeal this procedural ruling, though the standard for interlocutory appeal is high.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-2ac00a9fd8-REGN

Track record

53 reports on REGN

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Aug 12, 2026